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SHORT REPORT
Effective treatment of SIVcpz-induced 
immunodeficiency in a captive western 
chimpanzee
Hannah J. Barbian1,2, Raven Jackson‑Jewett3, Corrine S. Brown3, Frederic Bibollet‑Ruche2, Gerald H. Learn2, 
Timothy Decker2, Edward F. Kreider1,2, Yingying Li2, Thomas N. Denny4, Paul M. Sharp5, George M. Shaw1,2, 
Jeffrey Lifson6, Edward P. Acosta7, Michael S. Saag7, Katharine J. Bar2 and Beatrice H. Hahn1,2* 
Abstract 
Background: Simian immunodeficiency virus of chimpanzees (SIVcpz), the progenitor of human immunodeficiency 
virus type 1 (HIV‑1), is associated with increased mortality and AIDS‑like immunopathology in wild‑living chimpan‑
zees (Pan troglodytes). Surprisingly, however, similar findings have not been reported for chimpanzees experimentally 
infected with SIVcpz in captivity, raising questions about the intrinsic pathogenicity of this lentivirus.
Findings: Here, we report progressive immunodeficiency and clinical disease in a captive western chimpanzee (P. 
t. verus) infected twenty years ago by intrarectal inoculation with an SIVcpz strain (ANT) from a wild‑caught eastern 
chimpanzee (P. t. schweinfurthii). With sustained plasma viral loads of  105 to  106 RNA copies/ml for the past 15 years, 
this chimpanzee developed CD4+ T cell depletion (220 cells/μl), thrombocytopenia (90,000 platelets/μl), and persis‑
tent soft tissue infections refractory to antibacterial therapy. Combination antiretroviral therapy consisting of emtric‑
itabine (FTC), tenofovir disoproxil fumarate (TDF), and dolutegravir (DTG) decreased plasma viremia to undetectable 
levels (<200 copies/ml), improved CD4+ T cell counts (509 cell/μl), and resulted in the rapid resolution of all soft tissue 
infections. However, initial lack of adherence and/or differences in pharmacokinetics led to low plasma drug con‑
centrations, which resulted in transient rebound viremia and the emergence of FTC resistance mutations (M184V/I) 
identical to those observed in HIV‑1 infected humans.
Conclusions: These data demonstrate that SIVcpz can cause immunodeficiency and other hallmarks of AIDS in cap‑
tive chimpanzees, including P. t. verus apes that are not naturally infected with this virus. Moreover, SIVcpz‑associated 
immunodeficiency can be effectively treated with antiretroviral therapy, although sufficiently high plasma concentra‑
tions must be maintained to prevent the emergence of drug resistance. These findings extend a growing body of 
evidence documenting the immunopathogenicity of SIVcpz and suggest that experimentally infected chimpanzees 
may benefit from clinical monitoring and therapeutic intervention.
Keywords: SIVcpz, Chimpanzees, Antiretroviral therapy, AIDS, Drug resistance
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
SIVcpz infection is common and widespread in two chim-
panzee subspecies, the central chimpanzee (P. t. troglo-
dytes) in west central Africa and the eastern chimpanzee 
(P. t. schweinfurthii) in the Democratic Republic of the 
Congo (DRC) and countries to the east [1–5]. Two other 
subspecies in west Africa (P. t. verus) and Nigeria/Cam-
eroon (P. t. ellioti) are free of SIVcpz infection [3, 6, 7], 
because chimpanzees acquired this virus relatively more 
recently following the cross-species transmission and 
recombination of SIVs infecting monkeys on which 
they prey [8]. SIVcpz has been reported to have a nega-
tive impact on the health, reproduction and lifespan of 
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chimpanzees living in the wild. Comprehensive natu-
ral history studies in Gombe National Park, Tanzania, 
revealed that SIVcpz-infected chimpanzees have a 10–16 
fold increased risk of death and can develop CD4+ T 
cell depletion and AIDS-like immunopathology [9, 10]. 
Moreover, SIVcpz infected females were found to have 
lower birth rates and higher infant mortality compared to 
non-infected females [9], and one community with a high 
SIVcpz prevalence suffered a catastrophic population 
decline [11]. These results indicated that SIVcpz, unlike 
SIVs infecting other African primates such as sooty man-
gabeys (Cercocebus atys) or vervet monkeys (Chloroce-
bus pygerythrus), is pathogenic in its natural chimpanzee 
host [9–11].
P. t. verus apes comprise the great majority of captive 
chimpanzees worldwide, with 95% of founder animals 
in the United States having originated from West Africa 
[6, 12]. This explains the paucity of SIVcpz infections 
in captive populations, although a handful of SIVcpz 
infected P. t. troglodytes and P. t. schweinfurthii apes have 
been identified [13–16]. One such chimpanzee (Goran), 
who was rescued in Cameroon and studied in captivity 
for several years, developed CD4 T+ cell decline, severe 
thrombocytopenia, weight loss, and recurrent infections, 
and ultimately died of an AIDS-like illness [13]. Another 
chimpanzee (Noah), who was captured in the DRC and 
kept in a European primate center, also exhibited throm-
bocytopenia and some immunopathology [17]. Still 
another chimpanzee (Marilyn), who was wild-caught in 
west central Africa and utilized for biomedical research 
in the US, had normal laboratory and clinical findings, 
but died at age 26 after giving birth to still-born twins 
[14]. Finally, a number of bushmeat orphans identified 
in Gabon (GAB1 and GAB2) and Cameroon (CAM3, 
CAM4, CAM5, CAM13) were shown to be SIVcpz 
infected, but none of these could be studied prospectively 
since most died shortly after being rescued [15, 16]. Thus, 
only three naturally SIVcpz infected apes have been stud-
ied in captivity for an extended period of time.
Although most experimental lentivirus infections of 
chimpanzees were performed using HIV-1, a handful 
were infected with SIVcpz [17, 18]. Of six P. t. verus and 
two P. t. schweinfurthii apes exposed to SIVcpz by intra-
venous, intra-rectal or intra-vaginal routes, six became 
productively infected [18]. Three of these subsequently 
died of cardiomyopathy, a frequent cause of death in cap-
tive chimpanzees unrelated to SIVcpz infection, while 
the other three remained clinically healthy for as many 
as 16 years. The seeming absence of disease progression 
in these animals prompted speculation that the increased 
mortality associated with SIVcpz in the wild might be 
due to factors other than, or in addition to, their lentivi-
ral infection [17]. In addition, the possibility was raised 
that members of the P. t. verus subspecies, which are 
not naturally infected, may be more resistant to SIVcpz 
pathogenicity and/or that the SIVcpzANT strain used for 
these experimental infections was somehow attenuated 
[17]. Here, we studied one of these chimpanzees after his 
transfer from the Southwest National Primate Research 
Center to the Chimp Haven sanctuary, documenting dis-
ease progression and clinical immunodeficiency requir-
ing antiretroviral therapy.
Immunodeficiency in a western chimpanzee 
experimentally infected with SIVcpz
Cotton is a 40-year old male chimpanzee (also termed 
X115; Fig.  1a) who was experimentally infected with 
SIVcpzANT in 1996 after an earlier exposure to HIV-1/
IIIb [18]. The SIVcpz stock used for his infection was 
generated without interim in vitro culture by transferring 
peripheral blood mononuclear cells (PBMCs) from a nat-
urally infected eastern chimpanzee (Noah, Ch-No) [19] 
to an uninfected cage mate (Niko; Ch-Ni), and then using 
plasma collected during the acute infection phase for 
intra-rectal inoculation of Cotton and others [18]. Imme-
diately after SIVcpz infection, Cotton experienced CD4+ 
T cell depletion, which was followed by partial restora-
tion and then gradual decline of CD4+ T cell levels over 
time [17]. Cotton arrived at the US sanctuary Chimp 
Haven in 2006 and CD4+ T cell counts determined in 
2010 and 2014 showed 229 and 220  cells/μl, compared 
to ~1500  cells/μl before the infection [17]. Cotton also 
had low platelet counts of 101,000/μl and 90,000/μl in 
2014 and 2015 (normal range 130,500–379,930/μl [20]), 
low albumin levels (2.0  g/dl, normal range 3.3–4.1  g/dl 
[20]), and persistent soft tissue infections. The latter were 
first noted in 2009 and included a necrotizing infection 
of the hand. In 2014, he developed purulent anal fistulas 
that persisted despite debridement and administration of 
multiple rounds of broad-spectrum antibiotics delivered 
orally and intravenously over the course of more than 
three months. The low CD4+ T cell counts, thrombo-
cytopenia, hypoalbuminemia, and treatment-refractory 
soft tissue infections suggested that Cotton suffered from 
SIVcpz induced immunodeficiency.
To determine whether Cotton’s clinical symptoms were 
indeed a consequence of long-term SIVcpz infection, we 
determined his virus load in plasma samples taken as part 
of routine health examinations at Chimp Haven, as well 
as in a limited number of archived samples that were still 
available for years 1999–2006 (Fig. 1b). Since Cotton was 
exposed to HIV-1 prior to SIVcpzANT inoculation [18], 
we used a sensitive RT-qPCR method designed to amplify 
both HIV-1 and divergent SIVcpz strains by targeting a 
highly conserved region in the viral LTR [21]. This analy-
sis revealed plasma viral titers ranging from 54,000 RNA 
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copies/ml in 2001 to 1,441,000 RNA copies/ml in 2012 
(Fig. 1b), significantly higher than previously reported for 
some of these same time points [17]. Since our RT-qPCR 
approach was rigorously validated using both human and 
chimpanzee plasma samples of known viral content, the 
previous results likely represent an underestimation of 
Cotton’s viral loads. To exclude a low-level HIV-1 infec-
tion, we sequenced the 121 base pair LTR region used for 
RT-qPCR analysis (Fig. 1c). Amplicons were prepared for 
MiSeq sequencing (Nextera DNA Library Prep Kit, Illu-
mina, La Jolla, CA, USA) and the resulting reads were 
mapped to HIV-1 and SIVcpzPts reference sequences, 
since LTR sequences of the original SIVcpzANT iso-
late are not available [22]. This approach yielded 11,679 
paired-end reads, all of which were much more closely 
related to SIVcpzPts than to HIV-1 sequences, includ-
ing HIV-1/IIIb (Fig.  1c), indicating that Cotton is solely 
infected with SIVcpzANT.
Antiretroviral therapy of SIVcpz‑induced clinical 
immunodeficiency
Given Cotton’s laboratory and clinical findings, antiret-
roviral therapy (ART) was initiated on January 19, 2015, 
using a combination of the nucleoside reverse tran-
scriptase inhibitors tenofovir disoproxil fumarate (TDF) 
and emtricitabine (FTC), and the integrase strand trans-
fer inhibitor dolutegravir (DTG) at daily doses of 300, 
200 and 50  mg, respectively. This regimen was selected 
because it is recommended for HIV-1 infected adults 
[23] and potently inhibits both HIV-1 and HIV-2 in 
humans [24–27]. It also potently inhibits SIVmac, a 
virus even more distantly related to HIV-1 than SIVcp-
zANT, in experimentally infected rhesus macaques [28]. 
As shown in Fig.  1b, this regimen reduced SIVcpzANT 
viremia in Cotton to undetectable levels as determined 
by RT-qPCR (less than 200 copies/ml) at the first blood 
analysis 7  weeks after initiation of therapy (3/12/15). 
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Fig. 1 Virological evaluation of a western chimpanzee with long‑term experimental SIVcpz infection. a Cotton (X115) after initiation of antiviral 
therapy. Cotton was infected with a highly divergent SIVcpzPts strain (ANT) that differs from HIV‑1 in up to 48% of Env protein sequences. b Plasma 
virus loads (copies/ml) in Cotton over a 17‑year time span (sample dates are indicated). SIVcpzANT viral loads were determined using a sensitive vali‑
dated RT‑qPCR method that detects both SIVcpz and HIV‑1 infections [21]. A dashed red line indicates the onset of antiretroviral therapy (January 19, 
2015). c Nucleotide sequence alignment of HIV‑1 clade B and SIVcpzPts strains in the long terminal repeat (LTR) region (SIVcpzANT LTR sequences 
are not available). Sequences are compared to HIV‑1/IIIb, with  dots indicating sequence identity and dashes indicating gaps introduced for optimal 
alignment. LTR sequences from Cotton are much more closely related to SIVcpzPts than to HIV‑1 strains, indicating that he is solely infected with 
SIVcpzANT
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The treatment refractory anal fistulas healed completely 
within 4 weeks of onset of therapy, and CD4 T cell counts 
increased from 220 to 509 cells/μl after 2 years of treat-
ment (1/17/17), demonstrating the effectiveness of this 
regimen in achieving clinical improvement.
Cotton received ART daily by oral administration 
of crushed tablets dissolved in diluted fruit syrup, but 
caretakers noticed that he did not always ingest his 
medication completely. We thus continued to moni-
tor his virus load in blood samples obtained during his 
bi-annual medical evaluations. Indeed, nine months fol-
lowing initiation of therapy (9/25/15), virus was again 
detectable (4760 RNA copies/ml) in his plasma (Fig. 1b). 
To determine whether this rebound viremia was due 
to insufficient drug levels, one pre-treatment and four 
post-treatment plasma samples were sent to the Clini-
cal Pharmacology and Analytical Chemistry Core at the 
UNC Center for AIDS Research to quantitate plasma 
concentrations. This analysis revealed drug concentra-
tions of 1.08, 14.70 and 1.30  ng/ml for tenofovir (TFV, 
the metabolized product of TDF), FTC and DTG, respec-
tively, at the first time point of viral rebound (9/25/15) 
(Fig. 2a), which were significantly below the in vitro 50% 
HIV-1 inhibitory concentration  (IC50) of TFV (7.8 μg/ml) 
[29] and the 90% HIV-1 inhibitory concentrations  (IC90) 
of FTC (51 ng/ml) and DTG (64 ng/ml) [30, 31], respec-
tively. After caretakers improved oral administration by 
suspending the crushed tablets in more concentrated 
fruit syrup, plasma concentrations of TFV, FTC and DTG 
increased to 7.56, 46.90 and 47.20  ng/ml, respectively 
(Fig.  2a), which resulted in a concomitant reduction 
in viremia back to undetectable levels (Fig.  1b). How-
ever, these plasma concentrations were still significantly 
lower than typical human trough concentrations for this 
same regimen (54 ng/ml for TFV, 75 ng/ml for FTC and 
830  ng/ml for DTG) [32, 33]. Since FTC and TDF are 
metabolized in the kidney [34], while DTG is metabo-
lized in the liver [35], the uniformly low plasma concen-
trations are most likely due to insufficient drug uptake, 
although differences in pharmacokinetics between chim-
panzees and humans cannot be excluded. The timing 
of sample collection could have also played a role since 
the interval between plasma collection and the last drug 
administration was not recorded.
Development of drug resistance
Insufficient drug concentrations are known to facilitate 
the emergence of drug resistance [36]. We thus used sin-
gle genome amplification (SGA) to generate full-length 
pol gene sequences from pre- and post-treatment plasma 
samples. Briefly, plasma RNA was extracted, reverse 
transcribed, and the resulting cDNA end-point diluted to 
single template levels. Full-length pol genes were ampli-
fied and sequenced, and amplicons comprising more 
than one variant discarded [37]. This analysis revealed 
the emergence of M184V and M184I mutations in the 
conserved YMDD motif of the viral reverse transcriptase 
(RT) nine months after the onset of therapy (Fig. 2b). In 
HIV-1 infected humans, these mutations are known to 
confer resistance to FTC and to represent a first indica-
tion of a failing ART regimen [36, 38]. Viruses contain-
ing the M184I (ATG to ATA) mutation usually emerge 
first, but are rapidly outcompeted by viruses containing 
the M184V (ATG to GTG) mutation [39] due to their 
enhanced replication fitness [40]. Interestingly, this 
was not the case in Cotton where both M184I (ATG to 
ATA) and M184V (ATG to GTA) were observed at viral 
rebound, but M184I remained the predominant muta-
tion (Fig.  2b). Importantly, other mutations known to 
be associated with TFV and DVG resistance were not 
observed in any of the post-treatment sequences, and the 
most recent plasma sample, which was RT-qPCR nega-
tive (1/17/17), also failed to yield pol amplicons, suggest-
ing complete virus suppression.
The low plasma drug concentrations and emergence 
of FTC escape mutations suggested that the initial treat-
ment failed to fully suppress virus replication in Cot-
ton, despite viral load measurements below the limits of 
detection (<200  copies/ml) in the first post-treatment 
sample (3/12/15). Treatment interruptions of fully sup-
pressed HIV-1 infected humans usually result in the 
emergence of multiple viral lineages [41–44] that arise 
(See figure on next page.) 
Fig. 2 Plasma drug concentrations and emergence of FTC resistance. a Plasma concentrations of tenofovir (TFV, blue), emtricitabine (FTC, red), 
and dolutegravir (DTG, green) are shown for one pre‑treatment (11/25/14) and four post‑treatment samples (3/12/15, 9/25/15, 3/16/16, 1/17/17; 
viral loads corresponding to these time points are depicted in Fig. 1b). Limits of detection (LOD) for FTC and TFV/DTG are shown as red and blue 
dashed lines, respectively. The in vitro 90% HIV‑1 inhibitory concentrations  (IC90) for FTC and DTG are shown in red and green dotted lines, respectively. 
The in vitro 50% HIV‑1 inhibitory concentrations  (IC50) of TFV (7.8 μg/ml) is off‑scale and thus not shown. b Mutations in reverse transcriptase and 
integrase regions associated with TFV, FTC, and DTG drug resistance in HIV‑1 infection. A schematic representation of pol gene proteins is shown 
with common amino acid substitutions known to confer drug resistance indicated. Pol sequences generated from Cotton’s plasma using SGA 
approaches are listed by time points. Residues that are mutated compared to the pre‑treatment consensus sequence are highlighted in color (iden‑
tical residues are shown in grey). Pol sequences were also analyzed for less common substitutions associated with DTG resistance [54], but were free 
of such mutations
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stochastically from latently infected cells rather than from 
concurrent low-level replication [45]. To examine the ori-
gin of Cotton’s rebound virus, we used SGA to amplify 
3′ half viral genomes before and after treatment initiation 
[46]. Maximum likelihood analysis [47] of 194 full-length 
env gene sequences revealed that the majority of rebound 
viruses fell within the radiation of strains sampled imme-
diately prior to treatment (11/25/14), with only two 
post-treatment sequences clustering with viruses from 
2006 (Fig. 3). Thus, viral rebound in Cotton resulted pri-
marily from an outgrowth of low-level viremia rather 
than from reactivated latently infected cells. Our ability 
to amplify three pol gene sequences from the first post 
treatment sample (3/12/15) that was RT-qPCR negative 
is consistent with this (Fig.  2b). We also observed pro-
gressive diversification of pre-treatment SIVcpzANT env 
sequences over time, similar to what has been described 
for HIV-1 infected humans [48, 49]. Although these env 
sequences clustered almost exclusively by time point, 
this exaggerated bottlenecking is likely due to long sam-
pling intervals rather than differences in the pathways of 
SIVcpz and HIV-1 diversification. To examine this fur-
ther, we analyzed the C2-V5 region, which has previously 
been shown to diversify at a rate of approximately 1% per 
year in HIV-1 infected humans [49]. Using BEAST [50] 
to estimate the rate of SIVcpzANT diversification in the 
same C2-V5 region, we found a nearly identical substitu-
tion rate of 1.01% per year. Since the earlier report [49] 
had not used SGA to generate viral sequences nor BEAST 
for their analysis, we reexamined one subject whose viral 
sequences were endpoint diluted prior to PCR amplifica-
tion. This analysis yielded a substitution rate of 1.08% per 
year. Thus, the rate of SIVcpz evolution in chimpanzees 
appears to be very similar to that of HIV-1 in humans.
Conclusions
In summary, we report here the first case of progres-
sive immunodeficiency and clinical disease in a western 
chimpanzee experimentally infected with a naturally 
0.01
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Fig. 3 SIVcpzANT env gene evolution over time. A maximum likeli‑
hood tree depicting the phylogenetic relationships of full‑length env 
nucleotide sequences generated from Cotton’s plasma using SGA 
approaches is shown for a 16‑year time period. Samples are colored 
by time point (11/30/2000, purple; 7/19/2004, green; 11/01/2006, 
brown; 9/25/2012, magenta; 11/25/2014, blue; 9/25/2015, red; 
3/16/2016, black), with sequences from 2015 and 2016 representing 
rebound virus after insufficient suppression of viral replication due to 
low drug concentrations. Sequences were analyzed using PhyML [47] 
based on an evolutionary substitution model (TVM+I+G) selected 
by jModelTest [55]. The tree is rooted using the original SIVcpzANT 
sequence (U42720). Bootstrap values (of 1000 replicates) ≥80% are 
shown for major clades. The scale bar indicates 0.01 substitutions per 
site
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occurring strain of SIVcpzPts. While Cotton’s laboratory 
values did not meet the formal definition of AIDS (<200 
CD4+ T  cells/μl), his low CD4+ T cell counts, high 
plasma viral loads, treatment refractory soft tissue infec-
tions, and marked clinical improvement following reduc-
tion of plasma viremia by antiretroviral therapy indicates 
that SIVcpz caused his immunodeficiency. These results 
thus dispel the notion that SIVcpz is non-pathogenic in 
captive environments, or that SIVcpzANT is an attenu-
ated strain [17]. They also show that SIVcpz is pathogenic 
in chimpanzees that are not naturally infected with this 
virus. In addition to Cotton, two other experimentally 
SIVcpz infected P. t. verus chimpanzees are still alive. 
One (X176) was reported to have a CD4+ T cell count 
of 115 cells/μl, which represents an AIDS-defining crite-
rion, while the other (X284) maintained low viral loads 
and normal CD4 counts 16 years after infection [17]. The 
average time to AIDS progression in untreated HIV-1 
infected humans has been estimated to range between 10 
and 15  years. Thus, the natural history of SIVcpz infec-
tion, including the rate of disease progression, likely dif-
fers from that of HIV-1 infected humans, although the 
number of long-term followed apes is too small to draw 
definitive conclusions.
We also show that SIVcpz associated immunode-
ficiency can be effectively treated with antiretroviral 
therapy, which decreased plasma viremia in Cotton to 
undetectable levels within 7 weeks and increased CD4+ 
T cell counts to above 500 cells/μl within 2 years after 
onset of therapy, although low plasma drug concentra-
tions resulted in the emergence of FTC resistance muta-
tions. A considerable number of HIV-1 and SIVcpz 
infected chimpanzees are still housed in US primate 
centers. This study, together with previous reports of 
disease progression in HIV-1 infected captive chimpan-
zees [51–53], indicates that animals with high viremia 
and reduced CD4+ T cell counts are at risk of devel-
oping AIDS and should be treated to prevent clini-
cal disease. However, difficulties in maintaining strict 
adherence of daily oral administration and possible 
chimpanzee-specific differences in pharmacokinetics 
will require careful monitoring of drug concentrations 
and virus suppression. This is also true for Cotton, who 
currently has undetectable viral loads, but whose low 
plasma concentrations of TFV and DFV place him at 
high risk of developing further resistance and treatment 
failure.
Abbreviations
SIVcpz: simian immunodeficiency virus of chimpanzees; HIV‑1: human immu‑
nodeficiency virus type 1; AIDS: acquired immunodeficiency syndrome; SGA: 
single genome amplification; ART: antiretroviral therapy; DTG: dolutegravir; 
TDF: tenofovir disoproxil fumarate; TFV: tenofovir; FTC: emtricitabine; SIVmac: 
simian immunodeficiency virus of macaques.
Authors’ contributions
HJB designed and executed most experiments, and analyzed all data. RJJ and 
CSB provided veterinary care and clinical information for Cotton. EFK, GHL and 
PMS performed phylogenetic analyses. FBR, TD, YL and TND provided technical 
assistance. MSS, GMS, KJB, EPA and JL provided medical and treatment advice. 
HJB and BHH wrote the manuscript with input from all authors. All authors 
read and approved the final manuscript.
Author details
1 Department of Microbiology, Perelman School of Medicine, University 
of Pennsylvania, Philadelphia, PA, USA. 2 Department of Medicine, Perel‑
man School of Medicine, University of Pennsylvania, 409 Johnson Pavilion, 
3610 Hamilton Walk, Philadelphia, PA 19104‑6076, USA. 3 ChimpHaven, Inc., 
Keithville, LA, USA. 4 Duke Human Vaccine Institute, Duke University School 
of Medicine, Durham, NC, USA. 5 Institute of Evolutionary Biology, and Centre 
for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, UK. 
6 AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick 
National Laboratory for Cancer Research, Frederick, MD, USA. 7 Department 
of Medicine and Center for AIDS Research, University of Alabama at Birming‑
ham, Birmingham, AL, USA. 
Acknowledgements
We would like to thank Ron Collman for helpful advice, the staff of Chimp 
Haven for sample collection, the Duke Human Vaccine Institute for CD4+ 
T cell count determination, Angela Kashuba, Mackenzie Cottrell, and John 
Dohnal at the University of North Carolina Center for AIDS Research, and 
Kevin J. Ryan at the University of Alabama at Birmingham for determination 
of plasma drug concentrations, Jerilyn Pecotte and the staff of the Southwest 
National Primate Research Center for accessing archived plasma samples, and 
Shivani Sethi for artwork and manuscript preparation. In addition, we wish to 
thank ViiV Healthcare (Jim Demarest) and Gilead Sciences (Romas Geleziunas) 
for donating the antiretroviral drugs for Cotton’s treatment.
Competing interests
The authors declare that they have no competing interests.
Availability of data and material
SIVcpzANT env, pol and LTR sequences are available at GenBank under the 
accession codes KY989584‑KY989948.
Ethics approval and consent to participate
Blood collection from SIVcpz infected chimpanzees occurred in the context of 
health evaluations and was approved by the Institutional Animal Care and Use 
Committees of Chimp Haven and the Southwest National Primate Research 
Center.
Funding
This work was supported by grants from the National Institutes of Health to 
BHH (R37 AI50529, R01 AI120810, P30 AI 045008) and EFK (F30 AI 112426), and 
federal funds from the National Cancer Institute, National Institutes of Health, 
under contract HHSN261200800001E to JL. The content of this publication 
does not necessarily reflect the views or policies of the Department of Health 
and Human Services, nor does mention of trade names, commercial products, 
or organizations imply endorsement by the U.S. government. HJB was funded 
by a training grant in Emerging Infectious Diseases (T32 AI 055400).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 27 April 2017   Accepted: 25 May 2017
References
 1. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, et al. 
Chimpanzee reservoirs of pandemic and nonpandemic HIV‑1. Science. 
2006;313(5786):523–6.
Page 8 of 9Barbian et al. Retrovirology  (2017) 14:35 
 2. Santiago ML, Lukasik M, Kamenya S, Li Y, Bibollet‑Ruche F, Bailes E, 
et al. Foci of endemic simian immunodeficiency virus infection in 
wild‑living eastern chimpanzees (Pan troglodytes schweinfurthii). J Virol. 
2003;77(13):7545–62.
 3. Santiago ML, Rodenburg CM, Kamenya S, Bibollet‑Ruche F, Gao F, Bailes E, 
et al. SIVcpz in wild chimpanzees. Science. 2002;295(5554):465.
 4. Van Heuverswyn F, Li Y, Bailes E, Neel C, Lafay B, Keele BF, et al. Genetic 
diversity and phylogeographic clustering of SIVcpzPtt in wild chimpan‑
zees in Cameroon. Virology. 2007;368(1):155–71.
 5. Li Y, Ndjango JB, Learn GH, Ramirez MA, Keele BF, Bibollet‑Ruche F, et al. 
Eastern chimpanzees, but not bonobos, represent a simian immunodefi‑
ciency virus reservoir. J Virol. 2012;86(19):10776–91.
 6. Switzer WM, Parekh B, Shanmugam V, Bhullar V, Phillips S, Ely JJ, et al. 
The epidemiology of simian immunodeficiency virus infection in a large 
number of wild‑ and captive‑born chimpanzees: evidence for a recent 
introduction following chimpanzee divergence. AIDS Res Hum Retrovi‑
ruses. 2005;21(5):335–42.
 7. Prince AM, Brotman B, Lee D‑H, Andrus L, Valinsky J, Marx P. Lack of 
evidence for HIV type 1‑related SIVcpz infection in captive and wild chim‑
panzees (Pan troglodytes verus) in West Africa. AIDS Res Hum Retroviruses. 
2002;18(9):657–60.
 8. Bailes E, Gao F, Bibollet‑Ruche F, Courgnaud V, Peeters M, Marx PA, et al. 
Hybrid origin of SIV in chimpanzees. Science. 2003;300(5626):1713.
 9. Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, et al. 
Increased mortality and AIDS‑like immunopathology in wild chimpan‑
zees infected with SIVcpz. Nature. 2009;460(7254):515–9.
 10. Terio KA, Kinsel MJ, Raphael J, Mlengeya T, Lipende I, Kirchhoff CA, et al. 
Pathologic lesions in chimpanzees (Pan trogylodytes schweinfurthii) 
from Gombe National Park, Tanzania, 2004–2010. J Zoo Wildl Med. 
2011;42(4):597–607.
 11. Rudicell RS, Holland Jones J, Wroblewski EE, Learn GH, Li Y, Robertson JD, 
et al. Impact of simian immunodeficiency virus infection on chimpanzee 
population dynamics. PLoS Pathog. 2010;6(9):e1001116.
 12. Ely JJ, Dye B, Frels WI, Fritz J, Gagneux P, Khun HH, et al. Subspecies com‑
position and founder contribution of the captive U.S. chimpanzee (Pan 
troglodytes) population. Am J Primatol. 2005;67(2):223–41.
 13. Etienne L, Nerrienet E, LeBreton M, Bibila GT, Foupouapouognigni Y, Rous‑
set D, et al. Characterization of a new simian immunodeficiency virus 
strain in a naturally infected Pan troglodytes troglodytes chimpanzee with 
AIDS related symptoms. Retrovirology. 2011;8(1):4.
 14. Gilden R, Arthur L, Robey W, Kelliher J, Graham C, Fischinger P. HTLV‑III 
antibody in a breeding chimpanzee not experimentally exposed to the 
virus. Lancet. 1986;327(8482):678–9.
 15. Peeters M, Honare C, Huet T, Bedjabaga L, Ossari S, Bussi P, et al. Isolation 
and partial characterization of an HIV‑related virus occurring naturally in 
chimpanzees in Gabon. AIDS. 1989;3(10):625–30.
 16. Nerrienet E, Santiago ML, Foupouapouognigni Y, Bailes E, Mundy NI, 
Njinku B, et al. Simian immunodeficiency virus infection in wild‑caught 
chimpanzees from Cameroon. J Virol. 2005;79(2):1312–9.
 17. Greenwood EJD, Schmidt F, Kondova I, Niphuis H, Hodara VL, Clissold L, 
et al. Simian immunodeficiency virus infection of chimpanzees (Pan trog-
lodytes) shares features of both pathogenic and non‑pathogenic lentiviral 
infections. PLoS Pathog. 2015;11(9):e1005146.
 18. Heeney JL, Rutjens E, Verschoor EJ, Niphuis H, ten Haaft P, Rouse S, 
et al. Transmission of simian immunodeficiency virus SIVcpz and the 
evolution of infection in the presence and absence of concurrent 
human immunodeficiency virus type 1 infection in chimpanzees. J Virol. 
2006;80(14):7208–18.
 19. Peeters M, Fransen K, Delaporte E, Van den Haesevelde M, Gershy‑Damet 
GM, Kestens L, et al. Isolation and characterization of a new chimpanzee 
lentivirus (simian immunodeficiency virus isolate cpz‑ant) from a wild‑
captured chimpanzee. AIDS. 1992;6(5):447–51.
 20. Ihrig M, Tassinary LG, Bernacky B, Keeling ME. Hematologic and serum 
biochemical reference intervals for the chimpanzee (Pan troglodytes) 
categorized by age and sex. Comp Med. 2001;51(1):30–7.
 21. Etienne L, Eymard‑Duvernay S, Aghokeng A, Butel C, Monleau M, Peeters 
M. Single real‑time reverse transcription‑PCR assay for detection and 
quantification of genetically diverse HIV‑1, SIVcpz, and SIVgor strains. J 
Clin Microbiol. 2013;51(3):787–98.
 22. Vanden Haesevelde MM, Peeters M, Jannes G, Janssens W, van der 
Groen G, Sharp P, et al. Sequence analysis of a highly divergent HIV‑
1‑related lentivirus isolated from a wild captured chimpanzee. Virology. 
1996;221(2):346–50.
 23. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for 
the use of antiretroviral agents in HIV‑1‑infected adults and adolescents. 
Department of Health and Human Services. http://www.aidsinfo.nih.gov/
ContentFiles/AdultandAdolescentGL.pdf. Accessed Jan 2017 (page F‑3).
 24. Treviño A, Cabezas T, Lozano AB, García‑Delgado R, Force L, Fernández‑
Montero JM, et al. Dolutegravir for the treatment of HIV‑2 infection. J Clin 
Virol. 2015;64:12–5.
 25. Saravolatz LD, Saag MS. Emtricitabine, a new antiretroviral agent 
with activity against HIV and hepatitis B virus. Clin Infect Dis. 
2006;42(1):126–31.
 26. Raffi F, Rachlis A, Stellbrink H‑J, Hardy WD, Torti C, Orkin C, et al. Once‑
daily dolutegravir versus raltegravir in antiretroviral‑naive adults with 
HIV‑1 infection: 48 week results from the randomised, double‑blind, non‑
inferiority SPRING‑2 study. Lancet. 2013;381(9868):735–43.
 27. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Teno‑
fovir DF in antiretroviral‑experienced patients: results from a 48‑week, 
randomized, double‑blind study. AIDS. 2002;16(9):1257–63.
 28. Del Prete GQ, Smedley J, Macallister R, Jones GS, Li B, Hattersley J, et al. 
Short Communication: comparative evaluation of coformulated inject‑
able combination antiretroviral therapy regimens in simian immuno‑
deficiency virus‑infected rhesus macaques. AIDS Res Hum Retroviruses. 
2015;32(2):163–8.
 29. Mesquita PMM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, et al. 
Intravaginal ring delivery of tenofovir disoproxil fumarate for preven‑
tion of HIV and herpes simplex virus infection. J Antimicrob Chemother. 
2012;67(7):1730–8.
 30. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmaco‑
dynamic and drug‑interaction profile of the integrase inhibitor dolutegra‑
vir. Clin Pharmacokinet. 2013;52(11):981–94.
 31. Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins 
B, et al. Pharmacokinetics and safety of single‑dose tenofovir disoproxil 
fumarate and emtricitabine in HIV‑1‑infected pregnant women and their 
infants. Antimicrob Agents Chemother. 2011;55(12):5914–22.
 32. Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, et al. Anti‑
viral activity, safety, and pharmacokinetics/pharmacodynamics of 
dolutegravir as 10‑day monotherapy in HIV‑1‑infected adults. AIDS. 
2011;25(14):1737–45.
 33. Blum MR, Chittick GE, Begley JA, Zong J. Steady‑state pharmacokinetics of 
emtricitabine and tenofovir disoproxil fumarate administered alone and 
in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751–9.
 34. Dando TM, Wagstaff AJ. Emtricitabine/tenofovir disoproxil fumarate. 
Drugs. 2004;64(18):2075–82.
 35. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics 
and safety of S/GSK1349572, a next‑generation HIV integrase inhibitor, in 
healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.
 36. Clavel F, Hance AJ. HIV drug resistance. New Engl J Med. 
2004;350(10):1023–35.
 37. Salazar‑Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, 
et al. Deciphering human immunodeficiency virus type 1 transmission 
and early envelope diversification by single‑genome amplification and 
sequencing. J Virol. 2008;82(8):3952–70.
 38. Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV 
infection. Int J Clin Pract. 2004;58(5):504–10.
 39. Schuurman R, Nijhuis M, Rv Leeuwen, Schipper P, Jong Dd, Collis P, et al. 
Rapid changes in human immunodeficiency virus type 1 RNA load and 
appearance of drug‑resistant virus populations in persons treated with 
lamivudine (3TC). J Infect Dis. 1995;171(6):1411–9.
 40. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilen‑
burg AB, et al. Reduced replication of 3TC‑resistant HIV‑1 variants in 
primary cells due to a processivity defect of the reverse transcriptase 
enzyme. EMBO J. 1996;15(15):4040–9.
 41. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chip‑
man JG, et al. Large number of rebounding/founder HIV variants emerge 
from multifocal infection in lymphatic tissues after treatment interrup‑
tion. Proc Natl Acad Sci USA. 2015;112(10):E1126–34.
Page 9 of 9Barbian et al. Retrovirology  (2017) 14:35 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 42. Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, et al. 
Origin of rebound plasma HIV includes cells with identical proviruses that 
are transcriptionally active before stopping of antiretroviral therapy. J 
Virol. 2016;90(3):1369–76.
 43. Bednar MM, Hauser BM, Zhou S, Jacobson JM, Eron JJ Jr, Frank I, et al. 
Diversity and tropism of HIV‑1 rebound virus populations in plasma level 
after treatment discontinuation. J Infect Dis. 2016;214(3):403–7.
 44. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, 
et al. Effect of HIV antibody VRC01 on viral rebound after treatment inter‑
ruption. New Engl J Med. 2016;375(21):2037–50.
 45. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, et al. HIV rebounds 
from latently infected cells, rather than from continuing low‑level replica‑
tion. Proc Natl Acad Sci USA. 2008;105(43):16725–30.
 46. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High multiplic‑
ity infection by HIV‑1 in men who have sex with men. PLoS Pathog. 
2010;6(5):e1000890.
 47. Guindon S, Dufayard J‑F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New 
algorithms and methods to estimate maximum‑likelihood phylogenies: 
assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307–21.
 48. Zanini F, Brodin J, Thebo L, Lanz C, Bratt G, Albert J, et al. Population 
genomics of intrapatient HIV‑1 evolution. eLife. 2015;4:e11282.
 49. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Far‑
zadegan H, et al. Consistent viral evolutionary changes associated with 
the progression of human immunodeficiency virus type 1 infection. J 
Virol. 1999;73(12):10489–502.
 50. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by 
sampling trees. BMC Evol Biol. 2007;7(1):214.
 51 Novembre FJ, de Rosayro J, Nidtha S, O’Neil SP, Gibson TR, Evans‑Strick‑
faden T, et al. Rapid CD4+ T‑cell loss induced by human immunodefi‑
ciency virus type 1NC in uninfected and previously infected chimpan‑
zees. J Virol. 2001;75(3):1533–9.
 52 Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O’Neil SP, Brown CR, 
et al. Development of AIDS in a chimpanzee infected with human immu‑
nodeficiency virus type 1. J Virol. 1997;71(5):4086–91.
 53 O’Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, Evans‑Strickfaden T, 
et al. Progressive infection in a subset of HIV‑1‑positive chimpanzees. J 
Infect Dis. 2000;182(4):1051–62.
 54 Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 
2017 update of the drug resistance mutations in HIV‑1. Top Antivir Med. 
2017;24(4):132–41.
 55 Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, 
new heuristics and high‑performance computing. Nat Methods. 
2012;9(8):772.
